Biomarin Pharmaceutical Inc $59.86

up +0.50


22/7/2014 10:03 AM  |  NASDAQ : BMRN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get BMRN Trend Analysis - it has underperformed the S&P 500 by 25%

Partner Headlines

  1. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  2. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  3. Benzinga's Top Upgrades

    Benzinga
  4. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  5. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga
  6. Top Trending Tickers On StockTwits For February 18

    Benzinga
  7. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  8. You Can No Longer Ignore Biotech

    GuruFocus
  9. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  10. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)

    Benzinga
  11. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on ...

    Benzinga
  12. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 ...

    Benzinga
  13. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  14. Benzinga's Top #PreMarket Gainers

    Benzinga
  15. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for Treatment ...

    Benzinga
  16. BioMarin Stock Trading Halted Today for FDA Endocrinologic and Metabolic ...

    Benzinga
  17. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga
  18. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  19. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer ...

    Benzinga
  20. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, ...

    Benzinga
  21. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor Phase ...

    Benzinga
  22. Roche

    IBD
  23. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  24. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  25. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  26. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast Cancer at ...

    Benzinga
  27. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga
  28. Market Primer: Friday, September 20: US Markets Fall As Investors Re-Evaluate

    Benzinga
  29. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  30. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  31. Benzinga's Volume Movers

    Benzinga
  32. Benzinga's Top Pre-Market Gainers

    Benzinga
  33. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate Risk/Reward, ...

    Benzinga
  34. Benzinga's Top Pre-Market Gainers

    Benzinga
  35. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, ...

    Benzinga
  36. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 2, ...

    GuruFocus
  37. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 14, ...

    GuruFocus
  38. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5, ...

    GuruFocus
  39. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  40. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 3, ...

    GuruFocus
  41. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5, ...

    GuruFocus
  42. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin Pharmaceutical

    Benzinga
  43. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 17, ...

    GuruFocus
  44. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 9, ...

    GuruFocus
  45. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 5, ...

    GuruFocus
  46. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5, ...

    GuruFocus
  47. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 6, ...

    GuruFocus
  48. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral with $46 ...

    Benzinga
  49. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 5, ...

    GuruFocus
  50. BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in ...

    Benzinga
Trading Center